Evaluation of Performance, Safety and Benefit of the Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation

Inclusion Criteria:

• The subject signed the informed consent form;

• The subject is ≥ 18 and ≤ 80 years old at surgery;

• The subject is in need of a tooth extraction prior to implant placement;

• All four bony walls are preserved after extraction;

• Minimum 8mm height of bone;

• Minimum 7mm thickness of lingual vestibular;

• The subject is willing and able to comply with all investigation related procedures (such as exercising oral hygiene and attending all follow-up visits);

• Full-mouth bleeding score (FMBS) lower than 25%;

• Full-mouth plaque score (FMPI) lower than 25%.

Exclusion Criteria:

• Subject with an acute infection (abscess) at the surgical site;

• Subject with untreated periodontitis or periodontal disease;

• Subject with autoimmune diseases or subjects that had received or were currentlyreceiving treatment with antiresorptive drugs (e.g., bisphosphonates), or steroidtherapy;

• Subject who is pregnant or breastfeeding;

• Subjects is a heavy smoker (>10 cigarettes a day);

• Subject with an inability to conduct basic oral hygiene (poor oral hygiene andmotivation);

• Subject with metabolic diseases (diabetes, hyperparathyroidism, osteomalacia);

• Subject with severe renal dysfunction and severe liver disease;

• Subject with known severe osteoporosis;

• Subject with multiple sclerosis and/or acromegaly;

• Subject follows radiotherapy;

• Subject with psychiatric disorders or under substance abuse (drug or alcohol);

• Subject who participates in other clinical trials interfering with the presentprotocol;

• Mucosal diseases in the areas to be treated.